Skip to main content

Advertisement

Table 2 Outcomes, depicted as median, mean, and 95 % CI of the mean. (not adjusted for age, muscle area, time since menopause, and duration of RA)

From: Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis

  BP-naïve group BP group  
  N Median Mean 95 %-CI of mean N Median Mean 95 %-CI of mean p-value
Cortical CSA (mm2) at 33 % of femur 40 314.43 323.22 308.72-337.73 20 298.61 296.43 284.70-308.17 0.043
Cortical thickness in mm at 33 % of the femur 40 4.209 4.285 4.054-4.517 20 4.017 3.886 3.597-4.174 0.076
Medullary CSA (mm2) at 33 % of femur 40 180.40 191.66 172.82-210.49 20 196.68 227.65 177.84-277.45 0.466
Medullary CSA in relation to total CSA (%) 40 29.47 29.62 27.48-31.77 20 31.06 33.71 29.49-37.92 0.113
Cortical vBMD (mg/cm3) at 33 % of femur 40 1061.86 1062.03 1046.9-1077.1 20 1067.86 1036.03 994.02-1078.05 0.562
Total bone CSA (mm2) at 33 % of femur 40 623.11 639.91 613.87-665.94 20 643.31 649.58 586.36-712.81 0.925
Femoral index (%) 40 29.791 30.279 28.406-32.12 20 28.897 27.769 24.672-30.865 0.227
Polar SSI (mm3) 40 2640.840 2590.723 2411.798- 2769.648 20 2321.920 2277.980 2008.614- 2547.347 0.082